MANEHealthcare · Biotechnology

MANE Stock Forecast: Veradermics, Inc. Price Predictions for 2026-2027

Last close, 17 Nov 2026
$126
−1.88% on the day

The 7 Wall Street analysts covering Veradermics, Inc. hold a median 12-month price target of $188 — +49.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 5 of 100 as at 16 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.5B
Ticker Nerd rank
5/ 100
Median analyst target
$188
Analysts covering
7
Revenue$0.0
Operating income−$29.6M
Net income−$23.5M
Free cash flow−$14.5M
Quarterly, 6 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.4%
1M
+15.5%
From high
−19.7%
From low
+239.3%
$37
$157
Range since 4 Feb 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

MANE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Veradermics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 16 Nov 2026
5/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
57
Value
47
Issuance
24
Momentum
23
Size
22
Growth
18
Quality
11
Accruals
7
Volatility
4

Revisions (57): Analysts have, on balance, been raising their forecasts.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MANE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MANE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 4 Feb 2026Adjusted close, US dollars
$50$100$150$200Apr 26Jul 26Oct 26MANEHigh $204Median $188Low $172

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $172Median $188High $204

The green dot is the last close — the median target sits +49.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
10 Nov 2026CitigroupMaintainsBuy$160 → $175
9 Nov 2026Leerink PartnersMaintainsOutperform$135 → $150
22 Oct 2026B. Riley SecuritiesMaintainsBuy—
22 Oct 2026B. Riley SecuritiesMaintainsBuy$170 → $204
19 Oct 2026Cantor FitzgeraldReiteratesOverweight—
19 Oct 2026Cantor FitzgeraldReiteratesOverweight—
19 Oct 2026NeedhamMaintainsBuy—
19 Oct 2026NeedhamMaintainsBuy$164 → $172
16 July 2026CitigroupMaintainsBuy$135 → $160
16 July 2026CitigroupMaintainsBuy—
15 July 2026B. Riley SecuritiesInitiatesBuy—
15 July 2026B. Riley SecuritiesInitiatesBuy$170
15 July 2026NeedhamMaintainsBuy$136 → $164
15 July 2026NeedhamMaintainsBuy—
7 July 2026JefferiesMaintainsBuy—
7 July 2026JefferiesMaintainsBuy$138 → $182
16 June 2026LifeSci CapitalInitiatesOutperform—
2 June 2026NeedhamInitiatesBuy—
18 May 2026CitigroupMaintainsBuy—
22 Apr 2026Leerink PartnersMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MANE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MANE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

MANE vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300350400Apr 26Jul 26Oct 26MANES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MANE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Veradermics, Inc. (MANE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−54.1×

Cheaper than 99% of US stocks

Price / sales
—
Price / book
6.8×

Cheaper than 13% of US stocks

EV / EBITDA
−66.8×

Cheaper than 96% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 29% of US stocks

Returns & dividend
Return on equity
−23.1%

Higher than 30% of US stocks

Return on assets
−16.8%

Higher than 21% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Veradermics, Inc. (MANE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Veradermics, Inc. has a market value of $5.5B and an enterprise value of $4.7B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$92.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$78.3M.

  • Shares outstanding: 41.8M.

  • Trailing P/E: −54.1×; forward P/E: −49.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Veradermics, Inc. employs 51 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

MANE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MANEVeradermics, Inc.$5.5B5
ERASErasca, Inc.$5.2B48
SRRKScholar Rock Holding Corp.$5.4B47
PTCTPTC Therapeutics, Inc.$5.1B64
DNTHDianthus Therapeutics, Inc.$4.9B77
COGTCogent Biosciences, Inc.$4.7B33
EWTXEdgewise Therapeutics, Inc.$4.7B69

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Veradermics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MANE news & analysis

Veradermics to Present at the Jefferies Global Healthcare Conference in London

Business Wire · 12 Nov 2026neutral

Veradermics announced that management will present at the Jefferies Global Healthcare Conference in London on November 19, 2026, at 8:30 a.m. GMT. A live webcast will be available on the company’s investor events page.

Why it matters — The conference appearance gives MANE watchers an opportunity to hear from company management through the scheduled presentation and webcast.

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Business Wire · 10 Nov 2026positive

Veradermics reported financial results for the third quarter ended September 30, 2026, and highlighted recent corporate and clinical progress. The excerpt notes advancement of VDPHL01’s development as a potential treatment for pattern hair loss in men and women.

Why it matters — MANE watchers may note the company’s reported quarterly results and progress on its potential pattern hair loss treatment.

Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss

Business Wire · 9 Nov 2026positive

Veradermics reported positive topline 12-month data from Part B of its Phase 2/3 Study ‘302’ evaluating investigational VDPHL01 in men with pattern hair loss. The company said the study achieved the highest reported hair count for VDPHL01 in its Phase 3 program to date.

Why it matters — The results provide an update on clinical progress for Veradermics’ investigational treatment for male pattern hair loss.

Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

Business Wire · 8 Nov 2026neutral

Veradermics announced an investor call and live webcast for November 9, 2026, at 8:00 a.m. ET, to review topline 12-month results from Part B of its Phase 3 Study ‘302 evaluating VDPHL01 in males with mild-to-moderate pattern hair loss.

Why it matters — The call will provide MANE watchers with an update on results from a late-stage clinical trial of the company’s VDPHL01 program.

FAQ

Frequently asked questions about MANE stock

What is the MANE stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Veradermics, Inc. have a median 12-month price target of $188, with estimates ranging from $172 to $204. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MANE stock a buy right now?

Of the 7 analysts covering Veradermics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Veradermics, Inc. 5 out of 100 across roughly 4,600 US stocks as at 16 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MANE?

As at 16 Nov 2026, Veradermics, Inc. ranks 5 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (57 of 100).

Will MANE stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +49.2% from the last close, and Ticker Nerd's factor model ranks Veradermics, Inc. 5 out of 100 as at 16 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MANE stock forecast for 2030?

No analyst covering Veradermics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MANE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $172 to $204 over the next 12 months.

What does Veradermics, Inc. do?

Veradermics, Incorporated is a late clinical-stage biopharmaceutical company focused on developing dermatology and aesthetic treatments. Its current pipeline centers on therapies for pattern hair loss, including VDPHL01, an oral, non-hormonal, extended-release minoxidil formulation designed for men and women.

What is the latest news on MANE?

The most recent item we track (Business Wire, 12 Nov 2026): "Veradermics to Present at the Jefferies Global Healthcare Conference in London". Veradermics announced that management will present at the Jefferies Global Healthcare Conference in London on November 19, 2026, at 8:30 a.m. GMT. A live webcast will be available on the company’s investor events page.

Company

About Veradermics, Inc.

Veradermics, Incorporated is a late clinical-stage biopharmaceutical company focused on developing dermatology and aesthetic treatments. Its current pipeline centers on therapies for pattern hair loss, including VDPHL01, an oral, non-hormonal, extended-release minoxidil formulation designed for men and women. The company is also developing additional product candidates and delivery technologies for common skin and hair-related conditions such as alopecia areata, common warts, molluscum contagiosum, and atopic dermatitis. Veradermics serves healthcare providers, dermatology clinicians, and medical researchers involved in treating adult and pediatric patients. Headquartered in New Haven, Connecticut, and incorporated in 2019, Veradermics operates as a focused biotech company addressing prevalent dermatologic conditions through targeted therapeutic development.

CEO Dr. Reid Waldman M.D. · 51 employees · United States · https://www.veradermics.com